allantoin has been researched along with Hyperuricemia in 7 studies
Hyperuricemia: Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The objective is to determine whether therapy with TNF inhibitors (TNFis) affects SUA levels in patients with systemic autoimmune rheumatic diseases (SARDs) and whether SUA changes correlate with pro-inflammatory cytokines or with the oxidative stress marker allantoin." | 7.91 | Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors. ( Hasikova, L; Herrmann, M; Hulejova, H; Kalikova, K; Kozlik, P; Mahajan, A; Pavlikova, M; Stiburkova, B; Zavada, J, 2019) |
| "Although hyperuricemia is suggested to increase allantoin production in both pro- and antioxidant manners, it remains undetermined whether it increases the serum concentration of allantoin." | 7.78 | Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients. ( Koga, M; Koyama, H; Kurajoh, M; Moriwaki, Y; Shoji, T; Sumida, C; Tsutsumi, Z; Yamamoto, A; Yamamoto, T, 2012) |
| " The objective is to determine whether therapy with TNF inhibitors (TNFis) affects SUA levels in patients with systemic autoimmune rheumatic diseases (SARDs) and whether SUA changes correlate with pro-inflammatory cytokines or with the oxidative stress marker allantoin." | 3.91 | Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors. ( Hasikova, L; Herrmann, M; Hulejova, H; Kalikova, K; Kozlik, P; Mahajan, A; Pavlikova, M; Stiburkova, B; Zavada, J, 2019) |
| "Although hyperuricemia is suggested to increase allantoin production in both pro- and antioxidant manners, it remains undetermined whether it increases the serum concentration of allantoin." | 3.78 | Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients. ( Koga, M; Koyama, H; Kurajoh, M; Moriwaki, Y; Shoji, T; Sumida, C; Tsutsumi, Z; Yamamoto, A; Yamamoto, T, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, P | 1 |
| Zhang, R | 1 |
| Liu, CX | 1 |
| Wu, SX | 1 |
| Pei, XD | 1 |
| Jiang, Y | 1 |
| Liu, XL | 1 |
| Wang, CH | 1 |
| Rodríguez-Rovira, I | 1 |
| López-Sainz, A | 1 |
| Palomo-Buitrago, ME | 1 |
| Pérez, B | 1 |
| Jiménez-Altayó, F | 1 |
| Campuzano, V | 1 |
| Egea, G | 1 |
| Ronda, L | 1 |
| Marchetti, M | 1 |
| Piano, R | 1 |
| Liuzzi, A | 1 |
| Corsini, R | 1 |
| Percudani, R | 1 |
| Bettati, S | 1 |
| Hasikova, L | 1 |
| Pavlikova, M | 1 |
| Hulejova, H | 1 |
| Kozlik, P | 1 |
| Kalikova, K | 1 |
| Mahajan, A | 1 |
| Herrmann, M | 1 |
| Stiburkova, B | 1 |
| Zavada, J | 1 |
| Meotti, FC | 1 |
| Jameson, GN | 1 |
| Turner, R | 1 |
| Harwood, DT | 1 |
| Stockwell, S | 1 |
| Rees, MD | 1 |
| Thomas, SR | 1 |
| Kettle, AJ | 1 |
| Kurajoh, M | 1 |
| Koyama, H | 1 |
| Shoji, T | 1 |
| Sumida, C | 1 |
| Yamamoto, A | 1 |
| Tsutsumi, Z | 1 |
| Moriwaki, Y | 1 |
| Yamamoto, T | 1 |
| Koga, M | 1 |
| CAPRAMARZANI, P | 1 |
7 other studies available for allantoin and Hyperuricemia
| Article | Year |
|---|---|
Computer-assisted in vitro reconstitution of purine degradation pathway to lower the purine content in food.
Topics: Adenosine; Allantoin; Animals; Cattle; Computers; Gout; Humans; Hyperuricemia; Purines | 2022 |
Hyperuricaemia Does Not Interfere with Aortopathy in a Murine Model of Marfan Syndrome.
Topics: Allantoin; Animals; Antioxidants; Aortic Aneurysm; Disease Models, Animal; Hyperuricemia; Male; Marf | 2023 |
A Trivalent Enzymatic System for Uricolytic Therapy of HPRT Deficiency and Lesch-Nyhan Disease.
Topics: Allantoin; Amidohydrolases; Animals; Carboxy-Lyases; Enzyme Therapy; Humans; Hyperuricemia; Hypoxant | 2017 |
Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allantoin; Antirheumatic Agents; Autoimmune Diseases; Bi | 2019 |
Urate as a physiological substrate for myeloperoxidase: implications for hyperuricemia and inflammation.
Topics: Allantoin; Cardiovascular Diseases; Humans; Hydrogen Peroxide; Hyperuricemia; Inflammation; NADPH Ox | 2011 |
Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Allantoin; Benzbromarone; Biomarkers; Case-Control Studies; Crea | 2012 |
[EXPERIMENTAL HYPERURICEMIA. RESEARCH ON RABBITS. (ALLANTOIN AND URIC ACID)].
Topics: Allantoin; Animals; Anuria; Blood; Edema; Hydantoins; Hyperuricemia; Kidney Tubules; Lagomorpha; Pat | 1963 |